B-intervention	0	9	Hydrosorb
I-intervention	9	10	®
O	11	17	versus
B-control	18	25	control
I-control	26	27	(
I-control	27	32	water
I-control	33	38	based
I-control	39	44	spray
I-control	44	45	)
O	46	48	in
O	49	52	the
O	53	63	management
O	64	66	of
B-condition	67	72	radio
I-condition	72	73	-
I-condition	73	80	induced
I-condition	81	85	skin
I-condition	86	94	toxicity
O	94	95	:
O	96	103	Results
O	104	106	of
O	107	118	multicentre
O	119	129	controlled
O	130	140	randomized
O	141	146	trial
O	146	147	.

O	148	150	To
O	151	157	report
O	158	161	the
O	162	170	efficacy
O	171	173	of
O	174	183	Hydrosorb
O	183	184	®
O	185	191	versus
O	192	199	control
O	200	201	(
O	201	206	water
O	207	212	based
O	213	218	spray
O	218	219	)
O	220	222	as
O	223	230	topical
O	231	240	treatment
O	241	243	of
O	244	249	grade
O	250	251	1
O	251	252	-
O	252	253	2
O	254	269	radiodermatitis
O	270	272	in
B-eligibility	273	281	patients
I-eligibility	282	283	(
I-eligibility	283	286	pts
I-eligibility	286	287	)
I-eligibility	288	295	treated
I-eligibility	296	299	for
I-eligibility	300	305	early
I-eligibility	306	311	stage
I-eligibility	312	318	breast
I-eligibility	319	325	cancer
I-eligibility	326	327	(
I-eligibility	327	329	BC
I-eligibility	329	330	)
I-eligibility	331	335	with
I-eligibility	336	341	normo
I-eligibility	342	354	fractionated
I-eligibility	355	367	radiotherapy
I-eligibility	368	369	(
I-eligibility	369	371	RT
I-eligibility	371	372	)
O	372	373	.

O	374	376	BC
O	377	380	pts
O	381	385	were
O	386	396	randomized
O	397	399	to
O	400	407	receive
O	408	414	either
O	415	424	Hydrosorb
O	424	425	®
O	426	427	(
O	427	428	A
O	428	429	)
O	430	432	or
O	433	438	water
O	439	444	based
O	445	450	spray
O	451	452	(
O	452	453	B
O	453	454	)
O	454	455	.

O	456	459	The
O	460	467	primary
O	468	476	endpoint
O	477	480	was
B-outcome-Measure	481	486	local
I-outcome-Measure	487	496	treatment
I-outcome-Measure	497	504	failure
O	505	512	defined
O	513	515	as
O	516	528	interruption
O	529	531	of
O	532	534	RT
O	535	542	because
O	543	545	of
O	546	550	skin
O	551	564	radiotoxicity
O	565	567	or
O	568	574	change
O	575	577	of
O	578	583	local
O	584	588	care
O	589	596	because
O	597	599	of
O	600	604	skin
O	605	615	alteration
O	615	616	.

O	617	626	Secondary
O	627	636	endpoints
O	637	641	were
O	641	642	:
B-outcome-Measure	643	653	evaluation
I-outcome-Measure	654	656	of
I-outcome-Measure	657	661	skin
I-outcome-Measure	662	673	colorimetry
O	673	674	,
B-outcome-Measure	675	679	pain
O	679	680	,
B-outcome-Measure	681	688	quality
I-outcome-Measure	689	691	of
I-outcome-Measure	692	696	life
O	696	697	.

B-total-participants	698	701	Two
I-total-participants	701	702	-
I-total-participants	702	709	hundred
I-total-participants	710	717	seventy
I-total-participants	717	718	-
I-total-participants	718	723	eight
O	724	727	pts
O	728	732	were
O	733	741	enrolled
O	741	742	.

O	743	748	There
O	749	753	were
B-total-participants	754	757	186
O	758	770	successfully
O	771	778	treated
O	779	782	pts
O	782	783	.

O	784	789	There
O	790	794	were
B-iv-bin-abs	795	797	60
B-outcome	798	799	"
I-outcome	799	807	failures
I-outcome	807	808	"
O	809	811	in
O	812	815	the
O	816	825	Hydrosorb
O	825	826	®
O	827	830	arm
O	830	831	,
O	832	835	and
B-cv-bin-abs	836	838	62
O	839	841	in
O	842	845	the
O	846	853	control
O	854	857	arm
O	858	859	(
O	859	860	p
O	860	861	=
O	861	862	0
O	862	863	.
O	863	865	72
O	865	866	)
O	866	867	,
O	868	871	but
O	872	878	mostly
O	879	886	without
O	887	899	interruption
O	900	902	of
O	903	906	the
O	907	909	RT
O	909	910	.

O	911	917	Twenty
O	917	918	-
O	918	922	four
O	923	926	pts
O	927	934	stopped
O	935	937	RT
O	938	941	for
O	942	947	local
O	948	952	care
O	952	953	.

O	954	957	The
O	958	965	average
O	966	974	absolute
B-outcome	975	984	reduction
I-outcome	985	987	of
I-outcome	988	1000	colorimetric
I-outcome	1001	1007	levels
O	1008	1015	between
O	1016	1019	day
O	1020	1022	28
O	1023	1026	and
O	1027	1030	day
O	1031	1032	0
O	1033	1036	was
B-iv-cont-mean	1037	1038	4
O	1039	1041	in
O	1042	1045	the
O	1046	1055	Hydrosorb
O	1055	1056	®
O	1056	1057	,
O	1058	1061	and
B-cv-cont-mean	1062	1063	4
I-cv-cont-mean	1063	1064	.
I-cv-cont-mean	1064	1065	2
O	1066	1068	in
O	1069	1072	the
O	1073	1078	water
O	1079	1084	spray
O	1085	1091	groups
O	1091	1092	,
O	1093	1105	respectively
O	1106	1107	(
O	1107	1108	p
O	1108	1109	=
O	1109	1110	0
O	1110	1111	.
O	1111	1113	36
O	1113	1114	)
O	1114	1115	.

B-iv-bin-abs	1116	1121	Forty
I-iv-bin-abs	1121	1122	-
I-iv-bin-abs	1122	1127	eight
O	1128	1136	patients
O	1137	1139	in
O	1140	1143	the
O	1144	1153	Hydrosorb
O	1153	1154	®
O	1155	1158	arm
O	1159	1162	had
O	1163	1164	a
B-outcome	1165	1168	VAS
I-outcome	1169	1170	>
I-outcome	1170	1171	2
O	1172	1178	versus
B-cv-bin-abs	1179	1181	51
O	1182	1185	pts
O	1186	1188	in
O	1189	1192	the
O	1193	1200	placebo
O	1201	1204	arm
O	1204	1205	,
O	1206	1207	i
O	1207	1208	.
O	1208	1209	e
O	1209	1210	.
B-iv-bin-percent	1211	1213	34
I-iv-bin-percent	1213	1214	%
O	1215	1218	and
B-cv-bin-percent	1219	1221	38
I-cv-bin-percent	1221	1222	%
O	1222	1223	,
O	1224	1236	respectively
O	1237	1238	(
O	1238	1239	p
O	1239	1240	=
O	1240	1241	0
O	1241	1242	.
O	1242	1244	45
O	1244	1245	)
O	1245	1246	.

O	1247	1248	A
O	1249	1260	significant
O	1261	1270	reduction
O	1271	1273	of
B-outcome	1274	1278	pain
O	1279	1282	was
O	1283	1291	observed
O	1292	1294	on
O	1295	1297	D7
O	1298	1301	and
O	1302	1305	D21
O	1306	1308	in
O	1309	1312	the
O	1313	1322	Hydrosorb
O	1322	1323	®
O	1324	1327	arm
O	1327	1328	.

O	1329	1332	The
O	1333	1340	present
O	1341	1346	study
O	1347	1353	showed
O	1354	1356	no
O	1357	1368	significant
O	1369	1379	difference
O	1380	1387	between
O	1388	1397	Hydrosorb
O	1397	1398	®
O	1399	1402	and
O	1403	1409	simple
O	1410	1415	water
O	1416	1421	spray
O	1422	1424	in
O	1425	1428	the
O	1429	1438	treatment
O	1439	1441	of
O	1442	1447	acute
O	1448	1453	radio
O	1453	1454	-
O	1454	1461	induced
O	1462	1472	dermatitis
O	1473	1477	even
O	1478	1480	if
O	1481	1486	there
O	1487	1490	was
O	1491	1492	a
O	1493	1498	trend
O	1499	1501	to
O	1502	1504	an
O	1505	1516	improvement
O	1517	1519	in
O	1520	1524	pain
O	1525	1527	at
O	1528	1531	the
O	1532	1537	first
O	1538	1543	weeks
O	1544	1549	after
O	1550	1553	the
O	1554	1563	treatment
O	1563	1564	.

O	1565	1575	Systematic
O	1576	1586	prevention
O	1587	1595	measures
O	1596	1599	and
O	1600	1606	modern
O	1607	1613	breast
O	1614	1620	cancer
O	1621	1633	radiotherapy
O	1634	1644	techniques
O	1645	1648	now
O	1649	1654	allow
O	1655	1664	excellent
O	1665	1677	tolerability
O	1677	1678	,
O	1679	1682	but
O	1683	1686	the
O	1687	1692	place
O	1693	1695	of
O	1696	1703	topical
O	1704	1713	treatment
O	1714	1716	to
O	1717	1725	optimize
O	1726	1730	this
O	1731	1743	tolerability
O	1744	1747	has
O	1748	1751	yet
O	1752	1754	to
O	1755	1757	be
O	1758	1765	defined
O	1765	1766	.

O	1767	1769	It
O	1770	1775	seems
O	1776	1780	that
O	1781	1784	the
O	1785	1789	most
O	1790	1799	important
O	1800	1804	part
O	1805	1807	of
O	1808	1811	the
O	1812	1816	skin
O	1817	1821	care
O	1822	1824	is
O	1825	1828	the
O	1829	1839	prevention
O	1840	1842	of
O	1843	1847	skin
O	1848	1857	reactions
O	1858	1863	using
O	1864	1867	new
O	1868	1875	adapted
O	1876	1886	techniques
O	1886	1887	,
O	1888	1890	as
O	1891	1895	well
O	1896	1898	as
O	1899	1905	strict
O	1906	1913	hygiene
O	1913	1914	.
